Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProF-001 versus oral fluconazole in recurrent vulvovaginal candidiasis
2019-000925-27Phase 2Completed
- Sponsor
- ProFem
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in recurrent vulvovaginal candidiasis (RVVC) and vulvovaginal candidiasis (VVC) comparing ProF-001 topical arm with Oral fluconazole arm (2 arms). Primary endpoint: Clinical relapse of vulvovaginal candidiasis during 12 months. Started May 2019; status: completed.
02
Drugs
Candiplusfluconazole
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on 2019-000925-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000925-27.